Wang Ying-jie, He Nian-hai, Niu Run-zhang, Liu Jun, Wen Hong-wei, Li Jia-jia, Wang Yu-ming
Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Zhonghua Gan Zang Bing Za Zhi. 2003 Aug;11(8):461-3.
To construct a novel hybrid artificial liver support system and evaluate its clinical efficacy in the treatment of hepatic failure.
A hybrid bioartificial liver support system consisting of plasma exchange device, charcoal perfusion column, and bioreactor cultured human or porcine hepatocytes was developed. 30 patients with hepatic failure were treated using this hybrid system.
Both the excellent rate and effectual rate of the artificial liver support system were 43.3% (13/30). The total effectual rate was 86.7%. Finally, eleven out of 30 patients recovered completely. Six patients were bridged to liver transplantation. Six patients (20%) died of hepatic failure and seven patients (23.3%) discharged due to worsening of disease.
The hybrid artificial liver support system has prominent liver support effects for hepatic failure, which can be regarded as an efficient measure for the treatment of severe hepatitis.
构建一种新型混合人工肝支持系统并评估其治疗肝衰竭的临床疗效。
研发一种由血浆置换装置、活性炭灌注柱和培养人或猪肝细胞的生物反应器组成的混合生物人工肝支持系统。使用该混合系统治疗30例肝衰竭患者。
人工肝支持系统的优良率和有效率均为43.3%（13/30）。总有效率为86.7%。最终，30例患者中有11例完全康复。6例患者过渡到肝移植。6例患者（20%）死于肝衰竭，7例患者（23.3%）因病情恶化出院。
混合人工肝支持系统对肝衰竭具有显著的肝支持作用，可被视为治疗重型肝炎的有效措施。
